|
|||||
|
|
||||||
© 1999 American Society for Clinical Oncology
Extranodal Follicular Dendritic Cell Tumor of the Abdominal WallArthur Skarin, MD, Consultant Editor
City of Hope National Medical Center, Departments of General Oncologic Surgery and Anatomic Pathology, Duarte, CA
A 62-year-old man presented with a lower abdominal mass and some abdominal and left-sided groin pain. Computed tomography showed that this mass extended maximally to 15 cm in diameter, arose from the anterior abdominal wall, and lacked visceral involvement despite an intra-abdominal expansile growth (Fig 1A and 1B). The remaining examination and laboratory and imaging workup did not suggest the presence of metastatic disease. A fine-needle aspiration of the mass was consistent with a poorly differentiated sarcoma. The patient underwent operative treatment, with excision of some overlying skin, and radical resection of the soft tissue mass. Although displaced by tumor from the abdominal wall, the parietal peritoneum was not violated (Fig 2). Closure involved a dual mesh reconstruction. Pathologic analysis revealed a fleshy tan neoplasm with focal necrosis and negative surgical margins (Fig 3). Histologic examination demonstrated a spindle cell neoplasm with a whorling storiform pattern (Fig 4). The immunohistochemical staining pattern, including CD21 positivity (Fig 5) and CD35 positivity (Fig 6), was consistent with a follicular dentritic cell tumor (FDCT). The patient, who recovered uneventfully and underwent adjuvant external-beam radiation therapy to the abdominal wall, is currently disease-free after 8 months.
Follicular dendritic cells (FDCs) are found in primary and secondary lymphoid follicles and play an essential role in antigen presentation for the B-cell compartment, as well as regulation of the germinal center reaction.1 The exact origin of FDCs remains unclear, and hematopoietic lineage origin or stromal-cell derivation have been proposed. Proliferation of FDCs can lead to benign reactive lesions or generate neoplastic conditions. The diagnosis of a FDCT can be made based on immunohistochemical CD21 and CD35 positivity and/or characteristic ultrastructural findings of long, complex, and occasionally interdigitating cytoplasmic processes joined by desmosomes.2 After initial case descriptions of tumors arising from follicular dendritic reticulum cells within lymphatic tissues,3-5 FDCTs have been increasingly recognized as a specific oncologic entity.6,7 The term follicular dendritic cell sarcoma is also used to describe the same entity. Fifty-one cases of FDCT have been described to date,8 and most of them have arisen in lymphatic tissue, primarily of the neck.9 Intra-abdominal tumor location can involve the liver, spleen, or pancreas, in addition to the mesenteric or retroperitoneal lymph nodes. FDC proliferations may also be associated with the hyaline-vascular type of Castleman disease or, rarely, Epstein-Barr viruspositive hepatic or splenic inflammatory pseudotumors.10 Only two patients with soft tissue FDCTs, both arising in the neck, have been described,6 but it is unclear whether these tumors originated in lymphatic tissue as well. Because FDCs normally occur only in lymphoid follicles, we assume that even the FDCT of our patient likely arose from lymphatic tissue within the abdominal wall, rather than in a truly "extranodal" tissue site. The immunohistochemical diagnosis of FDCT relies on markers characteristically expressed on FDCs, including CD21 and CD35, which recognize complement receptors C3d and C3b, respectively.7 In that sense, FDCTs are clearly distinct from interdigitating reticulum cell sarcomas (IRCSs) (CD45RB-negative, S100 protein-negative, and histiocytic markerpositive), of which 21 cases have been described to date.8 The clinical or histopathologic distinction between IRCSs and FDCTs may be quite difficult to make. IRCSs may display a more aggressive course.8 The clinical behavior of FDCTs resembles that of soft tissue sarcomas rather than that of lymphomas, with local recurrences in 36% and metastases in 28%.7 Intra-abdominal location has been linked to a worse prognosis.6 Although the optimal treatment for FDCT is not known because of the limited experience, it seems sensible to apply therapeutic guidelines similar to those used for soft tissue sarcomas of high grade. Complete surgical resection is the therapy of choice, with the possibility of adjuvant radiation or chemotherapy for large or deep lesions.7 Responses to "sarcoma-type" systemic treatment have been observed that should be considered in cases with high-risk clinicopathologic features.6 Our case illustrates that FDCT can occur within soft tissue without intimate proximity to major nodal drainage basins and that FDCT should be included in the differential diagnosis of soft tissue neoplasms. The optimal combination treatment for FDCT has yet to be defined. REFERENCES 1. Chan JKC: Proliferative lesions of follicular dendritic cells: An overview, including a detailed account of follicular dendritic cell sarcoma, a neoplasm with many faces and uncommon etiologic associations. Adv Anat Pathol 4:387-411, 1997 2. Perez-Ordonez B, Erlandson RA, Rosai J: Follicular dendritic cell tumor: Report of 13 additional cases of a distinctive entity. Am J Surg Pathol 20:944-955, 1996[Medline] 3. Van der Valk P, Ruiter DJ, Den Ottolander GJ, et al: Dendritic reticulum cell sarcoma? Four cases of a lymphoma probably derived from dendritic reticulum cells of the follicular compartment. Histopathology 6:269-287, 1982[Medline] 4. Monda L, Warnke R, Rosai J: A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation: A report of 4 cases. Am J Pathol 122:562-572, 1986[Abstract] 5. Weiss LM, Berry GJ, Dorfman RF, et al: Spindle cell neoplasms of lymph nodes of probable reticulum cell lineage: True reticulum cell sarcoma? Am J Surg Pathol 14:405-414, 1990[Medline] 6. Chan JK, Fletcher CD, Nayler SJ, et al: Follicular dendritic cell sarcoma: Clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized. Cancer 79:294-313, 1997[Medline] 7. Perez-Ordonez B, Rosai J: Follicular dendritic cell tumor: Review of the entity. Semin Diagn Pathol 15:144-154, 1998[Medline] 8. Fonseca R, Yamakawa M, Nakamura S, et al: Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review. Am J Hematol 59:161-167, 1998[Medline] 9. Andriko JW, Kaldjian EP, Tsokos M, et al: Reticulum cell neoplasms of lymph nodes: A clinicopathologic study of 11 cases with recognition of a new subtype derived from fibroblastic reticular cells. Am J Surg Pathol 22:1048-1058, 1998[Medline] 10. Arber DA, Weiss LM, Chang KL: Detection of Epstein-Barr virus in inflammatory pseudotumor. Semin Diagn Pathol 15:155-160, 1998[Medline] This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 1999 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|